AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery
Iambic official newsroom · Indexed industry source record · Source published: Mon Sep 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:23 GMT+0000 (Coordinated Universal Time)
Saved source excerpt
− Multi-year partnership applies Iambic’s AI platform to speed up small molecule drug discovery in immunology, neuroscience and oncology − Companies to pursue programs with both first-in-class and best-in-class potential, combining Iambic’s molecular superintelligence platform with AbbVie’s therapeutic area expertise NORTH CHICAGO, Ill., and SAN DIEGO, Sept. 21, 2026 – AbbVie (NYSE: ABBV) and Iamb
This is a cited excerpt from the source. Read the original link for the complete text. Automated indexing and topic classification do not constitute fact verification.